A5042598309- Monoclonal and Polyclonal Antibodies Research
- CAR-T cell therapy research
- HER2/EGFR in Cancer Research
- Radiopharmaceutical Chemistry and Applications
- Virus-based gene therapy research
- Glycosylation and Glycoproteins Research
- Immunotherapy and Immune Responses
- Cell Adhesion Molecules Research
- Viral Infectious Diseases and Gene Expression in Insects
- Cancer Immunotherapy and Biomarkers
- Angiogenesis and VEGF in Cancer
- Immune Cell Function and Interaction
- Nanofabrication and Lithography Techniques
- Nanowire Synthesis and Applications
- RNA Interference and Gene Delivery
- Cancer Cells and Metastasis
- Biosimilars and Bioanalytical Methods
- CRISPR and Genetic Engineering
- T-cell and B-cell Immunology
- Galectins and Cancer Biology
- Bacteriophages and microbial interactions
- Mesenchymal stem cell research
- Cancer Research and Treatments
- Transgenic Plants and Applications
- PARP inhibition in cancer therapy
Research Institute Hospital 12 de Octubre
2019-2025
Hospital Universitario 12 De Octubre
2018-2025
Spanish National Cancer Research Centre
2022-2025
Universidad Francisco de Vitoria
2022-2024
Merck (Spain)
2022-2024
Aarhus University
2014-2022
Inspiralia
2022
Instituto de Salud Carlos III
2022
Hospital Universitario Puerta de Hierro Majadahonda
2007-2016
Center of Molecular Immunology (Cuba)
2012-2014
Pericytes and mesenchymal stem cells (MSCs) are ontogenically related, in fact, no significant phenotypic differences could be observed by flow cytometry. Transcriptome analysis of human pericytes MSCs revealed that 43 genes were up-regulated more than 10-fold compared with MSCs. Identification Toll-like receptor 4 (TLR4) as one the most abundant RNA species respect to confirmation TLR4 expression on cell surface led us obtain a comprehensive overview program lipopolysaccharide...
The gene mutated in ataxia telangiectasia, ATM, has been implicated several cell functions such as cycle control and response to DNA damage insulin. PKB/Akt also the cellular insulin, gamma-radiation, control. Interestingly, lack of function vivo is able mimic some phenotypic abnormalities associated with telangiectasia (AT). Here we show that ATM a major determinant full activation insulin or gamma-radiation. This effect mediated through phosphatidylinositol 3-kinase domain specifically...
In this work we report synthetic adhesins (SAs) enabling the rational design of adhesion properties E. coli. SAs have a modular structure comprising stable β-domain for outer membrane anchoring and surface-exposed immunoglobulin domains with high affinity specificity that can be selected from large repertoires. are constitutively stably expressed in an coli strain lacking conserved set natural adhesins, directing robust, fast, specific bacteria to target antigenic surfaces cells. We...
The costimulation of immune cells using first-generation anti-4-1BB monoclonal antibodies (mAbs) has demonstrated anti-tumor activity in human trials. Further clinical development, however, is restricted by significant off-tumor toxicities associated with FcγR interactions. Here, we have designed an Fc-free tumor-targeted 4-1BB-agonistic trimerbody, 1D8N/CEGa1, consisting three single-chain variable fragments and anti-EGFR single-domain positioned extended hexagonal conformation around the...
Multiple myeloma is the second most common hematological malignancy in adults and remains an incurable disease. B cell maturation antigen (BCMA)–directed immunotherapy, including T cells bearing chimeric receptors (CARs) systemically injected bispecific engagers (TCEs), has shown remarkable clinical activity, several products have received market approval. However, despite promising results, patients eventually become refractory relapse, highlighting need for alternative strategies....
The redirection of T cell activity using bispecific antibodies is one the most promising cancer immunotherapy approaches currently in development, but it limited by cytokine storm-related toxicities, as well pharmacokinetics and tumor-penetrating capabilities current antibody formats. Here, we have engineered ATTACK (Asymmetric Tandem Trimerbody for Activation Cancer Killing), a novel cell-recruiting which combines three EGFR-binding single-domain (VHH; clone EgA1) with single CD3-binding...
BackgroundSolid tumour growth is the consequence of a complex interplay between cancer cells and their microenvironment. Recently, new global transcriptomic immune classification solid tumours has identified six subtypes (ISs) (C1–C6). Our aim was to specifically characterise ISs in colorectal (CRC) assess with consensus molecular (CMSs).MethodsClinical information, including CMSs ISs, were obtained from The Cancer Genome Atlas (TCGA) (N = 625). Immune cell populations, differential gene...
Abstract Fc-less bispecific T-cell engagers have reached the immuno-oncology market but necessitate continual infusion due to rapid clearance from circulation. This work introduces a programmable serum half-life extension platform based on fusion of human albumin sequences engineered with either null (NB), wild type (WT) or high binding (HB) FcRn affinity combined engager. We demonstrate in humanised FcRn/albumin double transgenic mouse model (AlbuMus) ability tune sequence fused BiTE-like...
Retargeting of T lymphocytes toward cancer cells by bispecific antibodies has demonstrated its therapeutic potential, with one such antibody approved for the treatment acute lymphoblastic leukemia (blinatumomab) and several other in clinical trials. However, improvement their efficacy selectivity solid tumors is still required. Here, we describe a novel tandem T-cell recruiting trispecific colorectal (CRC). This construct, termed engager (TriTE), consists CD3-specific single-chain Fv (scFv)...
T cells require two distinct signals for optimal activation. One is an antigen-specific signal and provided by engagement of the cell receptor (TCR). The second antigen-independent mediated surface molecule CD28 with members B7 family. To endow molecules antibody-type recognition, we have constructed chimeric single-chain antibody variable fragment (scFv)-CD28 molecules; following transfection genes encoding such constructs into Jurkat human line show that they are stably expressed as...
Mesenchymal stem cells (MSCs) are appealing as gene therapy cell vehicles given their ease of expansion and transduction. However, MSCs exhibit immunomodulatory proangiogenic properties that may pose a risk in use anticancer therapy. For this reason, we looked for strategy to confine determined location, compatible with clinical application. Human genetically modified express luciferase (MSC(luc)), seeded synthetic extracellular matrix (sECM) scaffold (sentinel scaffold) injected...
Abstract Glioblastoma is considered one of the most aggressive malignancies in adult and pediatric patients. Despite decades research no curative treatment available it thus remains associated with a very dismal prognosis. Although recent pre-clinical clinical studies have demonstrated feasibility chimeric antigen receptors (CAR) T cell immunotherapeutic approach glioblastoma, tumor heterogeneity loss remain among important challenges to be addressed. In this study, we identify...
Chimeric antigen receptor (CAR)-modified T cells have revolutionized the treatment of CD19-positive hematologic malignancies. Although anti-CD19 CAR-engineered autologous can induce remission in patients with B-cell acute lymphoblastic leukemia, a large subset relapse, most them disease. Therefore, new therapeutic strategies are clearly needed. Here, we report comprehensive study comparing engineered either expressing second-generation CAR (CAR-T19) or secreting CD19/CD3-targeting bispecific...
Immune checkpoint inhibitors have revolutionized cancer therapy, but many patients fail to respond or develop resistance, often due reduced T cell activity. Costimulation via 4-1BB has emerged as a promising approach enhance the effector function of antigen-primed cells. Bispecific cell-engaging (TCE) antibodies are an effective way provide tumor-specific receptor-mediated signaling tumor-infiltrating lymphocytes. mRNA-based delivery bispecific antibodies, offer novel immune responses while...
Relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) remains a challenging disease with dismal prognosis. Despite the revolutionary impact of CD19-directed chimeric antigen receptor (CAR19)-T cell therapy, >50% patients relapse within year. Both cell-intrinsic factors favoring immune escape and poor CAR-T persistence contribute significantly to clinical failure. Moreover, expression checkpoint receptors (ICRs) their ligands complex bone marrow (BM) microenvironment...